Pharmabiz2d
Ascendis Pharma, Novo Nordisk ink collaboration to develop & commercialize TransCon technology-based products in metabolic and cardiovascular diseases
Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary ...
Ascendis Pharma’s Strategic Partnership with Novo Nordisk Signals Strong Buy Rating Amid Growing Obesity Market
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...
Ascendis Pharma and Novo Nordisk Join Forces
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
Ascendis Pharma (ASND) Receives a Buy from Cantor Fitzgerald
In a report released today, Li Watsek from Cantor Fitzgerald maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a ...
Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate
Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...
Joplin Globe4d
Ascendant Resources Initiates Drill Program at Its Lagoa Salgada VMS Project
Program driven by reinterpreted geophysical data and new gravity survey targets adjacent to existing North and South Zone deposits.
The Pharma Letter4d
Ascendis and Novo Nordisk sign deal on metabolic and CV diseases
Ascendis Pharma (Nasdaq: ASND) has granted fellow Denmark-based Novo Nordisk (NOV: N) an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo ...